EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

RP11‐367G18.1 V2 enhances clear cell renal cell carcinoma progression via induction of epithelial–mesenchymal transition

I-Hung Shao, Pei-Hua Peng, Heng-Hsiung Wu, Ji-Lin Chen, Joseph Chieh-Yu Lai, Jeng-Shou Chang, Han-Tsang Wu, Kou-Juey Wu, See-Tong Pang, Kai-Wen Hsu iD

Cancer Medicine · 2023

DOI: 10.1002/cam4.5723 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von I-Hung Shao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Genome Research Center, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, RNA, Long Noncoding, Carcinoma, Kidney Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chang Gung Memorial Hospital, China Medical University, Taiwan, Ministry of Science and Technology, Taiwan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Metastasis is the end stage of renal cell carcinoma (RCC), and clear cell renal cell carcinoma (ccRCC) is the most common malignant subtype. The hypoxic microenvironment is a common feature in ccRCC and plays an essential role in the regulation of epithelial–mesenchymal transition (EMT). Accumulating evidence manifests that long non‐coding RNAs (lncRNAs) participate in RCC tumorigenesis and regulate hypoxia‐induced EMT. Here, we identified a lncRNA RP11‐367G18.1 induced by hypoxia, that was overexpressed in ccRCC tissues.

Methods

A total of 216 specimens, including 149 ccRCC tumor samples and 67 related normal kidney parenchyma tissue samples, were collected. To investigate the biological fucntions of RP11.367G18.1 in ccRCC, migration, invasion, soft agar colony formation, xenograft tumorigenicity assays, and tail vein and orthotopic metastatic mouse models were performed. The relationship between RP11‐367G18.1 and downstream signaling was analyzed utilizing reporter assay, RNA pull‐down, chromatin immunopreciptation, and chromatin isolation by RNA purification assays.

Results

Hypoxic conditions and overexpression of HIF‐1α increased the level of RP11‐367G18.1 . RP11‐367G18.1 induced EMT and enhanced cell migration and invasion through variant 2. Inhibition of RP11‐367G18.1 variant 2 reversed hypoxia‐induced EMT phenotypes. An in vivo study revealed that RP11‐367G18.1 variant 2 was required for hypoxia‐induced tumor growth and metastasis in ccRCC. Mechanistically, RP11‐367G18.1 variant 2 interacted with p300 histone acetyltransferase to regulate lysine 16 acetylation on histone 4 (H4K16Ac), thus contributing to hypoxia‐regulated gene expression. Clinically, RP11‐367G18.1 variant 2 was upregulated in ccRCC tissues, particularly metastatic ccRCC tissues, and it is linked to poor overall survival.

Conclusion

These findings demonstrate the prognostic value and EMT‐promoting role of RP11‐367G18.1 and indicate that this lncRNA may provide a therapeutic target for ccRCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellRNA, Long NoncodingCarcinomaKidney NeoplasmsAnimalsMiceHumansEpithelial-Mesenchymal TransitionCell Line, TumorCell ProliferationHypoxiaChromatinCell MovementGene Expression Regulation, NeoplasticTumor Microenvironment

Stichwörter der Autor:innen

H4K16Acclear cell renal cell carcinomaepithelial-mesenchymal transitionhypoxialncRNA RP11-367G18.1

Substanzen

RNA, Long NoncodingChromatin

Autor:innen und Institutionen

  • Cancer Genome Research Center, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.
  • Division of Urology, Department of Surgery, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.
  • Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
  • Department of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
  • Research Center for Cancer Biology, China Medical University, Taichung City, Taiwan.
  • Program for Cancer Biology and Drug Discovery, China Medical University, Taichung City, Taiwan.

ORCID-Profile: Kai-Wen Hsu

Förderung

  • Chang Gung Memorial Hospital
  • China Medical University, Taiwan
  • Ministry of Science and Technology, Taiwan

Zitieren

APA

Shao, I. H., Peng, P. H., Wu, H. H., Chen, J. L., Lai, J. C., Chang, J. S., Wu, H. T., Wu, K. J., Pang, S. T., & Hsu, K. W. (2023). RP11‐367G18.1 V2 enhances clear cell renal cell carcinoma progression via induction of epithelial–mesenchymal transition. Cancer Medicine. https://doi.org/10.1002/cam4.5723

Vancouver

Shao IH, Peng PH, Wu HH, Chen JL, Lai JC, Chang JS, et al. RP11‐367G18.1 V2 enhances clear cell renal cell carcinoma progression via induction of epithelial–mesenchymal transition. Cancer Medicine. 2023. doi:10.1002/cam4.5723

BibTeX
@article{Shao2023,
  author = {Shao, I-Hung and Peng, Pei-Hua and Wu, Heng-Hsiung and Chen, Ji-Lin and Lai, Joseph Chieh-Yu and Chang, Jeng-Shou and Wu, Han-Tsang and Wu, Kou-Juey and Pang, See-Tong and Hsu, Kai-Wen},
  title = {RP11‐367G18.1 V2 enhances clear cell renal cell carcinoma progression via induction of epithelial–mesenchymal transition},
  journal = {Cancer Medicine},
  year = {2023},
  doi = {10.1002/cam4.5723}
}
Kostenlos starten →